A positive test does not necessarily mean someone will develop dementia
For generations, Alzheimer's disease has arrived as a thief in the night — its biological work done long before anyone noticed the forgetting. Now, a protein in the blood called pTau217 offers science a way to read those early warnings, potentially decades before memory falters. Researchers in Singapore and beyond are carefully mapping the distance between detection and intervention, knowing that the power to see a disease coming carries its own weight of consequence. The question before medicine is not only whether it can find Alzheimer's early, but whether humanity is prepared for what that knowledge demands.
- A blood marker called pTau217 can detect Alzheimer's-related brain changes in healthy middle-aged adults years — even decades — before any cognitive symptoms emerge.
- Singapore's National Neuroscience Institute has validated the test in real clinical settings across diverse populations, finding its reliability holds beyond the controlled conditions of Western research cohorts.
- The FDA approved blood-based Alzheimer's diagnostics in 2025, and Singapore is already using pTau217 for patients showing cognitive symptoms, but experts warn that deploying it for healthy community screening remains premature.
- False positives pose a serious risk: a positive result does not guarantee someone will develop dementia, and the personal fallout — for insurance, employment, and mental wellbeing — remains largely unresolved.
- Clinical trials are now testing whether treating asymptomatic people who carry early biological markers can actually prevent or delay cognitive decline, with the drug donanemab among the candidates under investigation.
A simple blood test may one day catch Alzheimer's disease long before it begins to steal memory. Scientists have shown that a protein called pTau217, circulating in the bloodstream, can signal disease-related changes in the brain decades before cognitive symptoms appear. A Lancet study found that healthy middle-aged adults carrying these markers face a measurably higher risk of future decline — raising the tantalising possibility of intervening early enough to change the disease's course.
The gap between promise and practice, however, remains wide. Alzheimer's is driven by the slow accumulation of amyloid-beta plaques and tau tangles in the brain — changes that begin silently, long before anyone notices they are forgetting. Detecting a biological marker is not the same as predicting who will actually develop dementia. Some people with the markers never progress. Others do. That distinction is still an open problem.
In March 2026, Singapore's National Neuroscience Institute and Duke-NUS Medical School published findings on how pTau217 performs in real-world clinical settings — not tidy research cohorts, but actual patients with mixed conditions and diverse backgrounds. The results were encouraging: the test's cut-off points aligned closely with those established in Western populations, suggesting its reliability may extend across demographic groups.
Yet the ethical terrain grows more complex as the science advances. The US FDA approved blood-based Alzheimer's diagnostics in 2025, and Singapore's National Neuroscience Institute now uses pTau217 for patients already showing cognitive symptoms. But widespread screening of healthy people is not yet recommended. A positive result in someone without symptoms raises unresolved questions about insurability, employment, and peace of mind — and scientific opinion remains divided on whether such a result should even be considered diagnostic.
For now, the greatest value of these tests lies in supporting diagnosis for those already experiencing early cognitive impairment — helping clinicians identify who needs further evaluation, and reducing reliance on expensive scans or invasive procedures. A pilot study with primary care physicians is planned to test whether pTau217 can effectively triage patients toward specialist memory clinics. Meanwhile, clinical trials are underway to determine whether treating asymptomatic people with early biological markers — using drugs like donanemab, already approved in Singapore for early symptomatic Alzheimer's — can prevent or delay decline. Until those results arrive, blood tests remain a powerful tool for the symptomatic, not yet a window offered to the healthy.
A simple blood test might one day catch Alzheimer's disease decades before it steals someone's memory. Researchers in Singapore and beyond have begun demonstrating that certain proteins circulating in the bloodstream—particularly one called pTau217—can signal the presence of disease-related changes in the brain long before any cognitive symptoms appear. A recent study published in the Lancet showed that healthy middle-aged adults carrying these biological markers face a measurably higher risk of future cognitive decline. The promise is real: intervene early, disrupt the disease's progression, possibly prevent the worst from happening.
The challenge is that promise and practice remain separated by a significant gap. While new drugs can slow Alzheimer's progression in people already showing memory problems, there is still no cure for the neurodegenerative condition itself. The disease is driven by the toxic accumulation of amyloid-beta protein plaques and tau tangles in the brain—changes that begin decades before anyone notices they are forgetting things. Blood tests offer a way to detect these changes years in advance, but detecting a biological marker is not the same as predicting who will actually develop dementia. Some people with the markers never progress to cognitive impairment. Others do. Distinguishing between the two remains an open problem.
In March 2026, Singapore's National Neuroscience Institute and Duke-NUS Medical School published findings on how pTau217 performs in real-world clinical settings, not just in controlled research environments. The study examined patients in a tertiary memory clinic—people with mixed conditions, diverse backgrounds, the messy reality of actual medical practice. The results were encouraging: the cut-off points for pTau217 aligned closely with those established in Western populations, suggesting the test's reliability might extend across different demographic groups. Adeline Ng, an associate professor and senior consultant in neurology at the institute, noted that this was among the first local studies to evaluate the test's performance outside of research cohorts.
Yet even as the science advances, the practical and ethical questions multiply. The United States Food and Drug Administration approved blood tests for Alzheimer's diagnosis in 2025, and Singapore's National Neuroscience Institute now uses pTau217 testing for patients with cognitive symptoms. But using these tests for widespread screening of healthy people remains premature, according to experts. Anna Barron, an associate professor at Nanyang Technological University studying the neurobiology of aging, emphasized that a positive test does not necessarily mean someone will develop dementia. False positives loom as a critical challenge before these tests can be deployed in community screening programs. There is also the matter of validating them across diverse populations—work that is still underway.
The implications extend beyond medicine into the realm of personal consequence. If a blood test reveals Alzheimer's pathology in someone with no symptoms, what does that mean for their insurability? Their employment prospects? Their peace of mind? Ng pointed out that scientific opinion is currently divided on whether a positive result in an asymptomatic person should be considered diagnostic of the disease. "Using pTau217 as a screening test in people without symptoms is not recommended at this stage," she said, "because the implications of detecting Alzheimer's pathology before symptoms develop are complex and require careful counselling, follow-up and treatment considerations."
For now, the greatest value of blood-based biomarkers lies in a narrower application: supporting diagnosis in people already showing early signs of cognitive impairment. These tests can serve as triage tools, helping clinicians identify which patients are likely to have Alzheimer's pathology and would benefit from further testing or closer monitoring. This could reduce reliance on expensive amyloid PET scans or invasive lumbar punctures, particularly in settings where such tests are not readily available. The National Neuroscience Institute is planning a pilot study with primary care physicians to test whether pTau217 can effectively identify patients with cognitive symptoms who are at higher risk of Alzheimer's, so they can be referred to specialist memory clinics for earlier evaluation.
Meanwhile, clinical trials are underway to test whether treating people with early biological markers of Alzheimer's—but no symptoms—can actually prevent or delay cognitive decline. One such trial is examining donanemab, a monoclonal antibody that targets amyloid plaques in the brain, in asymptomatic people with early biological signs of the disease. Donanemab is already approved in Singapore for treating early symptomatic Alzheimer's. The results of these trials will help determine whether early detection can be paired with early treatment to change the disease's trajectory. Until then, blood tests remain a powerful diagnostic tool for those already showing cognitive problems, not yet a screening instrument for the healthy.
Citas Notables
While earlier studies have demonstrated the promise of pTau217 in research cohorts, this study is among the first locally to evaluate its performance in a real-world tertiary memory clinic setting, where patients are more diverse.— Adeline Ng, associate professor and senior consultant at the National Neuroscience Institute
Using pTau217 as a screening test in people without symptoms is not recommended at this stage, because the implications of detecting Alzheimer's pathology before symptoms develop are complex and require careful counselling, follow-up and treatment considerations.— Adeline Ng
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that Singapore is studying this separately from Western research?
Because the biomarkers might behave differently in different populations. If you only study Caucasian cohorts in Europe and North America, you don't know if the same blood test thresholds work for people of Chinese, Malay, Indian, or other backgrounds. Singapore's work validates that they do—at least for pTau217—but that validation has to happen locally.
So a positive test doesn't mean you'll get Alzheimer's?
Exactly. It means your brain shows the biological hallmarks of the disease. But some people with those hallmarks never develop symptoms. Others do, sometimes decades later. We don't yet know how to tell them apart.
That sounds like it could cause real harm—telling someone they have a disease they might never get.
That's the concern. If you test positive, you might face discrimination in insurance or employment. You might live in fear of a decline that never comes. That's why experts say screening healthy people right now is premature.
What's the test actually good for then?
For people who are already noticing memory problems or cognitive changes. In that context, the blood test can help a doctor figure out whether Alzheimer's is the cause, without needing expensive brain imaging or a spinal tap.
And the drugs—can they actually stop the disease?
Not yet. The new drugs can slow progression in people who already have symptoms. Whether they can prevent symptoms from ever appearing in people with just the biomarkers—that's what the clinical trials are trying to answer.
How long until we know?
These trials take years. But the fact that they're running at all suggests the field believes early intervention might be possible. We just don't have proof yet.